News
02-01-2023, 01:41 AM
Results from the SWOG S1416 clinical trial show that adding veliparib to chemotherapy can significantly extend progression-free survival (PFS) times in patients with triple-negative breast cancer (TNBC) that has a "BRCA-like" phenotype.
More... (https://www.news-medical.net/news/20230131/Adding-veliparib-to-chemotherapy-can-extend-progression-free-survival-in-patients-with-e2809cBRCA-likee2809d-breast-cancer.aspx)
More... (https://www.news-medical.net/news/20230131/Adding-veliparib-to-chemotherapy-can-extend-progression-free-survival-in-patients-with-e2809cBRCA-likee2809d-breast-cancer.aspx)